MARKET

SLS

SLS

Sellas Life Sciences Group Inc
NASDAQ
3.730
+0.200
+5.67%
Pre Market: 3.780 +0.05 +1.34% 04:02 02/09 EST
OPEN
3.590
PREV CLOSE
3.530
HIGH
3.830
LOW
3.550
VOLUME
19
TURNOVER
0
52 WEEK HIGH
5.18
52 WEEK LOW
0.9516
MARKET CAP
635.15M
P/E (TTM)
-12.9965
1D
5D
1M
3M
1Y
5Y
1D
Sellas Life Sciences Group stellt neue Therapien für AML mit Fokus auf Galinpepimut-S und SLS009 vor
Reuters · 5d ago
Sellas Life Sciences Group Showcases Novel Therapies Targeting Acute Myeloid Leukemia in Latest Corporate Presentation
Reuters · 5d ago
Weekly Report: what happened at SLS last week (0126-0130)?
Weekly Report · 02/02 09:31
Weekly Report: what happened at SLS last week (0119-0123)?
Weekly Report · 01/26 09:31
Mixed options sentiment in Sellas Life Sciences with shares down 1.75%
TipRanks · 01/22 22:00
Why I'm Selling Sellas Life Sciences Ahead Of The REGAL Reveal
Seeking Alpha · 01/19 13:07
Weekly Report: what happened at SLS last week (0112-0116)?
Weekly Report · 01/19 09:34
BRIEF-Sellas Life Sciences Enters Agreement With Impact-Aml To Expand SLS009 Clinical Program Into Europe
Reuters · 01/14 13:37
More
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.

Webull offers Sellas Life Sciences Group Inc stock information, including NASDAQ: SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLS stock methods without spending real money on the virtual paper trading platform.